Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | KRAS | P01116 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CCNK | O75909 | 1/20 | 0.34 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18399307 | 0.92 | GPR119 (0.45) | RXRARXRBRXRGGPR119MEN1 | |
| SCHEMBL21797023 | 0.83 | RXRA (0.40) | RXRARXRBRXRGGPR119KRAS | |
| SCHEMBL18399060 | 0.83 | RXRA (0.40) | RXRARXRBRXRGGPR119KRAS | |
| SCHEMBL21797025 | 0.83 | RXRA (0.40) | RXRARXRBRXRGGPR119KRAS | |
| SCHEMBL18399201 | 0.83 | RXRA (0.40) | RXRARXRBRXRGGPR119KRAS | |
| SCHEMBL28606491 | 0.83 | RXRA (0.40) | RXRARXRBRXRGGPR119KRAS | |
| SCHEMBL22873493 | 0.83 | RXRA (0.40) | RXRARXRBRXRGGPR119KRAS | |
| SCHEMBL18399150 | 0.83 | RXRA (0.37) | RXRARXRBRXRGGPR119KRAS | |
| SCHEMBL22723391 | 0.82 | GPR119 (0.44) | RXRARXRBRXRGGPR119MEN1 | |
| SCHEMBL18399332 | 0.82 | GPR119 (0.44) | RXRARXRBRXRGGPR119MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130339-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130339-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | RXRA 4584/4885RXRB 4530/4885RXRG 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.